John Mullinax, MD

Cancer Focus:
Adrenal Cancer, GIST (Gastrointestinal Stromal Tumor), Osteosarcoma, Sarcoma

 

Dr. John Mullinax is an Associate Member in the Sarcoma Department and Immunology Department of Moffitt Cancer Center and Associate Professor in the Department of Surgery at the University of South Florida Morsani College of Medicine. He is the Surgical Director of the Cellular Immunotherapy Program and the Associate Program Director for the Complex General Surgical Oncology fellowship at Moffitt.  Dr. Mullinax is board-certified in both Surgery and Complex General Surgical Oncology by the American Board of Surgery.  Dr. Mullinax’s primary clinical focus is the surgical management of patients with soft tissue sarcoma throughout the body, to include retroperitoneal sarcoma and gastrointestinal stromal tumors.  In addition to clinical duties, Dr. Mullinax has a laboratory focused on the immune response to soft tissue sarcoma. He is working to expand adoptive cell therapy to patients with advanced sarcoma. The work from his lab serves as the basis for a trial using tumor infiltrating lymphocytes to treat adolescent and young adult patients with advanced sarcoma.  A native Floridian, he earned his MD degree with honors from the University of South Florida. He completed a General Surgery Residency in the Department of Surgery at the University of South Florida.  He completed two fellowships: first a Surgical Oncology Fellowship at the Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland and another in Complex General Surgical Oncology at Moffitt Cancer Center. He represents the Moffitt Sarcoma Department in the international Transatlantic-Australasian Retroperitoneal Sarcoma Workgroup (TARPSWG).  His research has generated awards from the Society of Immunotherapy for Cancer, the Commission on Cancer of the American College of Surgeons, and Moffitt Cancer Center.   He is a Fellow of the American College of Surgeons and a member of the Alpha Omega Alpha honor medical society.   Nationally, he serves as a Governor in the American College of Surgeons and is a Councilor in the Florida Chapter of the American College of Surgeons.  

 

Education & Training

Board Certification:

• Surgery - Complex General Surgical Oncology

Fellowship:

• National Cancer Institute Surgery Branch - Surgical Oncology
• Moffitt Cancer Center - Complex General Surgical Oncology

Residency:

• University of South Florida - General Surgery
• University of South Florida - General Surgery

Medical School:

• University of South Florida - MD

Clinical Trial 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Dineen S, Mullinax J. ASO Author Reflections: Emphasizing Surgical Palliative Care in CGSO Fellowship Programs. Ann Surg Oncol. 2025 Sep. Pubmedid: 40924245.
• Dineen S, O'Leary C, Rajasekhara S, Mullinax J. Implementation of a Palliative Surgical Oncology Rotation to Complex General Surgical Oncology Fellowship Training. Ann Surg Oncol. 2025 Oct.32(10):7124-7130. Pubmedid: 40849382.
• Soupir A, Ospina OE, Hampton O, Churchman M, Radmacher M, Hedges D, McKean D, Agius P, Zeeshan S, Seligson ND, Pollock R, Liebner D, Chen JL, Tinoco G, Salhia B, McCarter M, Wilky BA, Miller BJ, Cavnar MJ, Groundland JS, Schneider BP, Riedlinger G, Edge SB, Moskaluk CA, Cardona K, Naqash AR, Gonzalez RJ, Mullinax JE, Joyce DM, Binitie O, Douglas Letson G, Naghavi AO, Druta M, Reed DR, Siegel EM, Teer JK, Fridley BL, Brohl AS. Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes. Nat Commun. 2025 May.16(1):4206. Pubmedid: 40328759. Pmcid: PMC12055966.
• Tirotta F, Fiore M, Bonvalot S, Strauss D, Rutkowski P, Gyorki DE, van Houdt WJ, Callegaro D, Albertsmeier M, Tzanis D, Cananzi F, Sicklick JK, Mullinax J, Wilkinson M, Grignol VP, Cardona K, Bouhadiba T, Novak M, Valeri S, Fairweather M, Ford SJ, Skoczylas J, Snow H, Hayes AJ, Hodson J, Raut CP, Gronchi A. Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study. EClinicalMedicine. 2025 Jun.84:103280. Pubmedid: 40521170. Pmcid: PMC12167443.
• van der Burg SJC, Fiore M, Rutkowski P, Albertsmeier M, Bonvalot S, Grignol VP, Raut CP, Cananzi FCM, Mullinax JE, Gyorki DE, Pennacchioli E, Ford SJ, Nessim C, Cardona K, Callegaro D, Skoczylas J, Lindner LH, Gronchi A, Van Houdt WJ. Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration. Ann Surg Oncol. 2025 Jul.32(7):5359-5366. Pubmedid: 40374864.
• Dugan MM, Beekman KE, DePalo DK, Parker LM, Elleson KM, Mullinax JE, Sarnaik AA, Sondak VK, Perez MC, Zager JS. The Use of Radar-Guided Localization to Identify Metastatic Melanoma After Neoadjuvant Immunotherapy. Ann Surg Oncol. 2025 Jul.32(7):5300-5305. Pubmedid: 40279056.
• Metts J, Rodriguez-Valentin M, Hensel J, Alfaro A, Snyder CW, Binitie O, Chebli C, Monforte H, Pilon-Thomas S, Mullinax J. Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors. Cytotherapy. 2025 Jan.27(1):29-35. Pubmedid: 39243253. Pmcid: PMC11668621.
• Aflatooni S, Dugan MM, Boby A, Ghali H, DePalo DK, Naqvi SMH, Mullinax JE, Zager JS. ASO Visual Abstract: Isolated Limb Infusion for Limb Threatening Sarcomas. Ann Surg Oncol. 2025 Jan.32(1):568-569. Pubmedid: 39446227.
• Turcotte S, Donia M, Gastman B, Besser M, Brown R, Coukos G, Creelan B, Mullinax J, Sondak VK, Yang JC, Rohaan MW, Marie Svane I, Lotze MT, Haanen JBAG, Goff SL. Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. J Immunother Cancer. 2025 Jan.13(1). Pubmedid: 39837618. Pmcid: PMC11752064.
• Karadimas T, Huynh TH, Chose C, Zervoudakis G, Clampitt B, Lapp S, Joyce D, Letson GD, Metts J, Binitie O, Mullinax JE, Lazarides A. Oncolytic Viral Therapy in Osteosarcoma. Viruses. 2024 Jul.16(7). Pubmedid: 39066301. Pmcid: PMC11281467.
• Beekman KE, DePalo DK, Parker LM, Elleson KM, Mullinax JE, Sarnaik AA, Sondak VK, Zager JS. Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study. Cancer Control. 2024 Jan.31. Pubmedid: 38429650. Pmcid: PMC10908225.
• Dugan MM, Aflatooni S, Mullinax JE, Zager JS. ASO Author Reflections: Isolated Limb Infusion for Extremity Sarcomas: Past, Present, and Future. Ann Surg Oncol. 2024 Dec.31(13):9283-9284. Pubmedid: 39306620.
• Aflatooni S, Dugan MM, Boby A, Ghali H, DePalo DK, Naqvi SMH, Mullinax JE, Zager JS. Isolated Limb Infusion for Limb-Threatening Sarcomas. Ann Surg Oncol. 2024 Dec.31(13):9272-9280. Pubmedid: 39256312.
• Levi S, Bank H, Mullinax J, Boland G. Precision Oncology in Melanoma and Skin Cancer Surgery. Surg Oncol Clin N Am. 2024 Apr.33(2):369-385. Pubmedid: 38401915.
• Liveringhouse CL, Palm RF, Bryant JM, Yang GQ, Mills MN, Figura ND, Ahmed KA, Mullinax J, Gonzalez R, Johnstone PA, Naghavi AO. Neoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal Sarcoma. Int J Radiat Oncol Biol Phys. 2023 Sep.117(1):123-138. Pubmedid: 36935026.
• Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023 Sep.8(18). Pubmedid: 37581943. Pmcid: PMC10561731.
• Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer. 2023 Oct.11(10). Pubmedid: 37802604. Pmcid: PMC10565316.
• Carr MJ, Sun J, Adams WA, Dugan MM, Naqvi SMH, Kim Y, Messina JL, Gonzalez RJ, Zager JS, Mullinax JE. Grade of Primary Cutaneous Leiomyosarcoma Dictates Risk for Metastatic Spread and Disease-Specific Mortality. Cancer Control. 2023 Jan.30. Pubmedid: 37876208. Pmcid: PMC10605670.
• Tseng WW, Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Ford SJ, Gonzalez RJ, Gladdy RA, Gyorki DE, Fairweather M, Lee KW, Albertsmeier M, van Houdt WJ, Fau M, Nessim C, Grignani G, Cardona K, Quagliuolo V, Grignol V, Farma JM, Pennacchioli E, Fiore M, Hayes A, Tzanis D, Skoczylas J, Almond ML, Mullinax JE, Johnston W, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Desai A, Voss R, Sanfilippo R, Jones RL, Baldini EH, Wagner AJ, Catton CN, Stacchiotti S, Thway K, Roland CL, Raut CP, Gronchi A. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2022 Nov.29(12):7335-7348. Pubmedid: 35767103.
• Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul.28(4):322-327. Pubmedid: 35880942. Pmcid: PMC9847472.
• Mullinax JE, Egger ME, McCarter M, Monk BJ, Toloza EM, Brousseau S, Jagasia M, Sarnaik A. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Cancer J. 2022 Jul.28(4):285-293. Pubmedid: 35880938. Pmcid: PMC9335895.
• Mullinax JE, Pilon-Thomas S. Adoptive Cell Therapy for Advanced Solid Tumors. Cancer J. 2022 Jul.28(4):255-256. Pubmedid: 35880933.
• Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 Dec.28(24):5317-5329. Pubmedid: 36215121. Pmcid: PMC10324027.
• Yang G, Yuan Z, Ahmed K, Welsh EA, Fulp WJ, Gonzalez RJ, Mullinax JE, Letson D, Bui M, Harrison LB, Scott JG, Torres-Roca JF, Naghavi AO. Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Transl Oncol. 2021 Oct.14(10):101165. Pubmedid: 34246048. Pmcid: PMC8274330.
• Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, Gonzalez R, Gyorki DE, Fairweather M, van Houdt WJ, Stoeckle E, Park JB, Albertsmeier M, Nessim C, Cardona K, Fiore M, Hayes A, Tzanis D, Skoczylas J, Ford SJ, Ng D, Mullinax JE, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Stacchiotti S, Jones RL, DeLaney T, Roland CL, Raut CP, Gronchi A. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol. 2021 Nov.28(12):7873-7888. Pubmedid: 33852100. Pmcid: PMC9257997.
• Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
• Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May.94:107481. Pubmedid: 33636562. Pmcid: PMC8205103.
• Hagerty BL, Torres MB, Drake J, Hernandez JM, Mullinax JE, Blakely AM, Davis JL. Trends and Predictors of Failure of Minimally Invasive Surgery for Gastric GIST. J Gastrointest Surg. 2021 May.25(5):1319-1322. Pubmedid: 33057943. Pmcid: PMC9615106.
• Broman KK, Joyce D, Binitie O, Letson GD, Gonzalez RJ, Choi J, Mullinax JE. Intraoperative Localization Using an Implanted Radar Reflector Facilitates Resection of Non-Palpable Trunk and Extremity Sarcoma. Ann Surg Oncol. 2021 Jun.28(6):3366-3374. Pubmedid: 33073344.
• Innamarato P, Morse J, Mackay A, Asby S, Beatty M, Blauvelt J, Kidd S, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors. BMC Cancer. 2021 Jun.21(1):756. Pubmedid: 34187428. Pmcid: PMC8243723.
• Mullinax JE, Hall M, Beatty M, Weber AM, Sannasardo Z, Svrdlin T, Hensel J, Richards A, Gonzalez RJ, Cox CA, Kelley L, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. J Immunother. 2021 Feb.44(2):63-70. Pubmedid: 33443972. Pmcid: PMC8111686.
• Naffouje SA, Sabesan A, Hallanger-Johnson J, Kirtane K, Gonzalez RJ, Mullinax J. Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1/T2 adrenocortical carcinoma: A propensity score-matched analysis. J Surg Oncol. 2021 Dec.124(8):1261-1271. Pubmedid: 34424540.
• Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
• Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
• Gerhardt CA, Belzarena AC, Henderson-Jackson E, Mullinax JE, Joyce DM. Intrapelvic melanocytic schwannoma resection with computer-assisted navigation. Radiol Case Rep. 2020 Nov.15(11):2385-2390. Pubmedid: 32994847. Pmcid: PMC7516168.
• Ruff SM, Rothermel LD, Diggs LP, Wach MM, Ayabe RI, Martin SP, Boulware D, Anaya D, Davis JL, Mullinax JE, Hernandez JM. Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford). 2020 Jul.22(7):1004-1010. Pubmedid: 31734237. Pmcid: PMC7771330.
• Boddu S, Walko CM, Bienasz S, Bui MM, Henderson-Jackson E, Naghavi AO, Mullinax JE, Joyce DM, Binitie O, Letson GD, Gonzalez RJ, Reed DR, Druta M, Brohl AS. Clinical Utility of Genomic Profiling in the Treatment of Advanced Sarcomas: A Single-Center Experience. JCO Precis Oncol. 2018 Nov.2:1-8. Pubmedid: 35135155.
• Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
• Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, Gronchi A. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. Eur J Surg Oncol. 2018 Jun.44(6):810-815. Pubmedid: 29452860.
• Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
• Li D, Mullinax JE, Aiken T, Xin H, Wiegand G, Anderson A, Thorgeirsson S, Avital I, Rudloff U. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. BMC Cancer. 2018 Jul.18(1):772. Pubmedid: 30064387. Pmcid: PMC6069886.
• Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One. 2018 Apr.13(4):e0196033. Pubmedid: 29694419. Pmcid: PMC5918896.
• Straughan DM, McLoughlin KC, Mullinax JE, Marciano BE, Freeman AF, Anderson VL, Uzel G, Azoury SDC, Sorber R, Quadri HS, Malech HL, DeRavin SS, Kamal N, Koh C, Zerbe CS, Kuhns DB, Gallin JI, Heller T, Holland SM, Rudloff U. The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. Clin Infect Dis. 2018 Apr.66(9):1427-1434. Pubmedid: 29145578. Pmcid: PMC6248449.
• Naghavi AO, Gonzalez RJ, Scott JG, Mullinax JE, Abuodeh YA, Kim Y, Binitie O, Ahmed KA, Bui MM, Saini AS, Zager JS, Biagioli MC, Letson D, Harrison LB, Fernandez DC. Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. Brachytherapy. 2017 Jul.15(4):495-503. Pubmedid: 27180128. Pmcid: PMC7771533.
• Naghavi AO, Gonzalez RJ, Scott JG, Kim Y, Abuodeh YA, Strom TJ, Echevarria M, Mullinax JE, Ahmed KA, Harrison LB, Fernandez DC. Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma. J Contemp Brachytherapy. 2017 Feb.9(1):20-29. Pubmedid: 28344600. Pmcid: PMC5346606.
• O'Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SMH, Kim Y, Gonzalez RJ, Zager JS. Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. Ann Surg Oncol. 2017 Dec.24(13):3842-3849. Pubmedid: 29019175. Pmcid: PMC7771340.
• Mullinax JE, Gonzalez RJ, Zager JS. Treatment of Soft Tissue Sarcoma: In reply to He and colleagues. J Am Coll Surg. 2017 Aug.225(2):349. Pubmedid: 28750715.
• Mullinax JE, Kroon HM, Thompson JF, Nath N, Mosca PJ, Farma JM, Bhati R, Hardmann D, Sileno S, O'Donoghue C, Perez M, Naqvi SM, Chen YA, Gonzalez RJ, Zager JS. Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. J Am Coll Surg. 2017 Apr.224(4):635-642. Pubmedid: 28214556. Pmcid: PMC7771304.
• Mullinax JE, Gonzalez RJ. Management of Truncal Sarcoma. Surg Clin N Am. 2016 Oct.96(5):1003-1013. Pubmedid: 27542639.
• Hanna C, Mullinax J, Friedman MS, Sanchez J. Jejunal diverticulosis found in a patient with long-standing pneumoperitoneum and pseudo-obstruction on imaging: a case report. Gastroenterol Rep (Oxf). 2016 Nov.4(4):337-340. Pubmedid: 26220890. Pmcid: PMC5193057.
• Xin HW, Ambe CM, Miller TC, Chen JQ, Wiegand GW, Anderson AJ, Ray S, Mullinax JE, Hari DM, Koizumi T, Godbout JD, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I. Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin. J Cancer. 2016 Jun.7(9):1142-1151. Pubmedid: 27326258. Pmcid: PMC4911882.
• Rashid OM, Mullinax JE, Pimiento JM, Meredith KL, Malafa MP. Robotic Whipple Procedure for Pancreatic Cancer: The Moffitt Cancer Center Pathway. Cancer Control. 2015 Jul.22(3):340-351. Pubmedid: 26351891.
• Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep.110(3):275-284. Pubmedid: 25042700. Pmcid: PMC6301031.
• Langan RC, Gill F, Raiji MT, Mullinax JE, Pittaluga S, Pandalai P, Davis J, Perkins K, Avital I, Rudloff U. Autoimmune pancreatitis in the autoimmune lymphoproliferative syndrome (ALPS): a sheep in wolves' clothing?. Pancreas. 2013 Mar.42(2):363-366. Pubmedid: 23407489. Pmcid: PMC3573327.
• Xin HW, Ambe CM, Ray S, Kim BK, Koizumi T, Wiegand GW, Hari D, Mullinax JE, Jaiswal KR, Garfield SH, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I. Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division. J Cancer. 2013 Jul.4(6):447-457. Pubmedid: 23901343. Pmcid: PMC3726705.
• Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, Langan RC, Burka D, Herrmann MA, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut. 2013 Dec.62(12):1777-1786. Pubmedid: 23411027. Pmcid: PMC6993136.
• Ray S, Langan RC, Mullinax JE, Koizumi T, Xin HW, Wiegand GW, Anderson AJ, Stojadinovic A, Thorgeirsson S, Rudloff U, Avital I. Establishment of human ultra-low passage colorectal cancer cell lines using spheroids from fresh surgical specimens suitable for in vitro and in vivo studies. J Cancer. 2012 Oct.3:196-206. Pubmedid: 22606209. Pmcid: PMC3354415.
• Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U, Avital I. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. J Cancer. 2012 Oct.3:231-240. Pubmedid: 22670157. Pmcid: PMC3366478.
• Mullinax JE, Hernandez JM, Toomey P, Villadolid D, Bowers C, Cooper J, Rosemurgy AS. Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status. Am J Surg. 2012 Nov.204(5):704-708. Pubmedid: 23140830.
• Xin HW, Hari DM, Mullinax JE, Ambe CM, Koizumi T, Ray S, Anderson AJ, Wiegand GW, Garfield SH, Thorgeirsson SS, Avital I. Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells. 2012 Apr.30(4):591-598. Pubmedid: 22331764. Pmcid: PMC3492937.
• Mullinax JE, Allins A, Avital I. Laparoscopic appendectomy for Amyand's hernia: a modern approach to a historic diagnosis. J Gastrointest Surg. 2011 Mar.15(3):533-535. Pubmedid: 21069473. Pmcid: PMC6936321.
• Mullinax JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. Cancer Control. 2011 Jul.18(3):177-187. Pubmedid: 21666580.
• Clark W, Hernandez J, McKeon BA, Kahn A, Morton C, Toomey P, Mullinax J, Ross S, Rosemurgy A. Surgery residency training programmes have greater impact on outcomes after pancreaticoduodenectomy than hospital volume or surgeon frequency. HPB (Oxford). 2010 Feb.12(1):68-72. Pubmedid: 20495648. Pmcid: PMC2814407.
• Clark W, Hernandez J, McKeon B, Villadolid D, Al-Saadi S, Mullinax J, Ross SB, Rosemurgy AS. Surgical shunting versus transjugular intrahepatic portasystemic shunting for bleeding varices resulting from portal hypertension and cirrhosis: a meta-analysis. Am Surg. 2010 Aug.76(8):857-864. Pubmedid: 20726417.
• Hernandez J, Morton C, Clark W, Mullinax J, Mathur A, Marcadis A, Babel N, Ross S, Goldin S, Rosemurgy A. Pancreaticoduodenectomy for suspected periampullary cancers: the mimes of malignancy. HPB (Oxford). 2009 Nov.11(7):578-584. Pubmedid: 20495710. Pmcid: PMC2785953.
• Hernandez J, Mullinax J, Clark W, Toomey P, Villadolid D, Morton C, Ross S, Rosemurgy A. Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg. 2009 Jul.250(1):76-80. Pubmedid: 19561479.
• Hernandez J, Cowgill SM, Al-Saadi S, Villadolid D, Ross S, Kraemer E, Shapiro M, Mullinax J, Cooper J, Goldin S, Zervos E, Rosemurgy A. An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection. Ann Surg Oncol. 2008 Mar.15(3):807-814. Pubmedid: 18181000.

• Title: The TINKS Trial
  Award Number: 810828-1224-00
  Sponsor: ISABELLA SANTOS FOUNDATION
  Mullinax, J. (PD/PI)
• Title: Biomarkers of Response in Pediatric Patients Following Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes
  Award Number: GC2025-012
  Sponsor: V FOUNDATION
  Mullinax, J. (PD/PI)
• Title: Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy
  Award Number: 5K08CA252642-05
  Sponsor: National Cancer Institute (NCI)
  Mullinax, J. (PD/PI)

• Voted top doctor in Surgical Oncology in Tampa Magazine's Top Doctors 2025         
• Voted top doctor in Surgical Oncology in Tampa Magazine's Top Doctors 2024     
• Elected to a three-year term as governor-at-large representing the Fellows in the Florida Chapter of the American College of Surgeons